iMEAN
PrivateLast Round
Grant
Jul 9, 2020
Company Overview
iMEAN is a biotechnology company that provides R&D support services using digital organisms and mathematical modeling for the agriculture, industrial biotechnology, and healthcare sectors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iMEAN Comparables
Compare iMEAN with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Yokogawa Electric Corporation | 73% | |
| Differential Bio | 72% | |
| New Wave Biotech | 69% |
iMEAN Funding Rounds
Historical fundraising activity
Key People
Founding team and executive leadership
iMEAN Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Région Occitanie | Grant |
| French Ministry of the Economy, Finance and Industrial and Digital Sovereignty | Grant |
| Bpifrance | Grant |
| Nubbo | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 25, 2026
Grew 18% QoQ, from 17 to 20 employees.
- Jul 9, 2020
Received grant funding from Bpifrance and other French entities.
Recent news
Latest coverage and updates
- attends_eventOct 12, 2026
iMEAN attends ABIM2026 in Switzerland on Oct 20th-22nd '26 and showcases predictive modelling for biocontrol, plant health, and responses to environmental stress.
- attends_eventOct 9, 2026
iMEAN participates in the Functional Structural Plant Models 2026 Conference in France from Oct 12th–16th '26, with representatives presenting work during the poster lightning talk sessions.
- attends_eventOct 9, 2026
iMEAN participates in the Functional Structural Plant Models 2026 Conference in France from Oct 12th to 16th '26, with representatives presenting work during the poster lightning talk sessions.
iMEAN Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about iMEAN's valuation, stock price, and market status.
Is iMEAN a public or private company?
iMEAN is a private company.
What is the current stock price of iMEAN?
iMEAN is a private company, so its shares have no public market price. Caplight tracks iMEAN's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is iMEAN worth (valuation)?
Valuation information for iMEAN is not publicly available.
Can I buy iMEAN stock?
iMEAN shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was iMEAN's last funding round?
iMEAN's most recent funding round was Grant on July 9, 2020.
Who are the main investors in iMEAN?
Key investors in iMEAN include Région Occitanie, French Ministry of the Economy, Finance and Industrial and Digital Sovereignty, Bpifrance, Nubbo.
Will iMEAN IPO soon?
No public IPO plans have been announced for iMEAN.
How can I track iMEAN secondary market activity?
Caplight tracks bids, offers, and trades in iMEAN's shares on secondary markets.